Across 691 adults followed for 80 weeks, roughly 39% to 52% on the higher doses reached OSA remission or mild disease, versus about 12% to 24% on placebo.
Recap by typeshit. Full story at Physician's Weekly.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
8:58
Constable, who bills herself as a peptide expert, lists side effects she links to the unapproved triple agonist. Her claims, not trial data, so weigh them accordingly.
In an ADJUST-T1D follow-up, former semaglutide users lost a median 3.6 points of time in range within 3 months, even while on automated insulin delivery.
Loading…